PEDIATRIC NEUROLOGY, vol.110, pp.59-63, 2020 (SCI-Expanded)
Background: Aprepitant is a neurokinin-1 receptor antagonist approved for the treatment of chemotherapy-induced nausea. We aimed to investigate the safety and efficacy of aprepitant in patients with subacute sclerosing panencephalitis.